BELLUS Health CEO and leadership

Roberto Bellini has served as President and CEO of BELLUS Health since January 1, 2010. Bellini previously oversaw the licensing and partnering activities of BELLUS Health Inc. His experience includes responsibility for the investment and operational activities of Picchio Pharma Inc., a joint venture healthcare investment firm owned by FMRC Family Trust and Power Technology Investment Corporation. Bellini is a sitting member of the Board of Directors of BELLUS Health. He has broad ties in the community and has served on numerous fundraising committees for the following institutions: l’Institut du cancer de Montréal, the Sarah Cook Fund for the Cedars Cancer Institute, l’Institut de Gériatrie, le Musée d’art contemporain de Montréal and la Fondation Quebec Jeunes. Bellini holds a Bachelor of Science in Biochemistry from McGill University.

Dr. Catherine Bonuccelli has served as Chief Medical Officer of BELLUS Health since August 26, 2019. Dr. Bonuccelli is a pediatric pulmonologist with over 20 years of pharmaceutical experience with significant expertise in clinical and product development of respiratory and non-respiratory products. Dr. Bonuccelli held a number of leadership positions focusing on the late-stage clinical development of large and small molecule programs in the respiratory and inflammation therapeutic areas. During her more than 20-year tenure with AstraZeneca, she played a number of roles, including Global Medicines Clinical Vice President for the Inflammation, Neuroscience, & Respiratory Therapeutic Area, and Therapy Area Clinical Vice President, Respiratory and Inflammation. Dr. Bonuccelli subsequently spent more than four years serving as US Medical Affairs Respiratory Therapeutic Area Head for GlaxoSmithKline. Dr. Bonuccelli earned her MD, and was an Intern, Resident, Research Fellow, and Clinical Fellow, at Johns Hopkins University in Baltimore, Maryland. She is a member of several prominent boards.

Ramzi Benamar serves as Chief Financial Officer and is a member of DBV’s Executive Committee, responsible for leading financial strategy, overseeing DBV’s finance team, and managing the financing wellbeing of the company. Mr. Benamar brings more than 20 years of industry experience with significant financial leadership capabilities, a focus on capital deployment strategies, and a rich background in both R&D and commercial biotechnology companies. Prior to joining DBV in January 2020, Mr. Benamar served as Vice President and Head of Financial Planning and Analysis at Spark Therapeutics where he was responsible for financial management, financial analysis & planning, business partnering and performance reporting. He contributed to the transition of Spark Therapeutics from a late-stage to a commercial stage company, including being part of the team that launched the first gene therapy in the United States. Spark Therapeutics was acquired by Roche Holdings AG in December 2019 for $4.3B. Before joining Spark Therapeutics, Mr. Benamar held various Finance and Operations positions of increasing responsibilities at Shire Plc, Johnson & Johnson, and Merck and Co. Originally from Lyon, France, Mr. Benamar speaks fluent French and English. Mr. Benamar earned both his M.B.A and B.B.A in Marketing and Finance from Temple University, and his Master of Healthcare and Pharmaceutical Business Administration from University of the Sciences in Philadelphia.

Roberto Bellini has served as President and CEO of BELLUS Health since January 1, 2010. Bellini previously oversaw the licensing and partnering activities of BELLUS Health Inc. His experience includes responsibility for the investment and operational activities of Picchio Pharma Inc., a joint venture healthcare investment firm owned by FMRC Family Trust and Power Technology Investment Corporation. Bellini is a sitting member of the Board of Directors of BELLUS Health. He has broad ties in the community and has served on numerous fundraising committees for the following institutions: l’Institut du cancer de Montréal, the Sarah Cook Fund for the Cedars Cancer Institute, l’Institut de Gériatrie, le Musée d’art contemporain de Montréal and la Fondation Quebec Jeunes. Bellini holds a Bachelor of Science in Biochemistry from McGill University.